ILARIS (canakinumab) Patient Assistance Program
Don’t let the high cost of brand specialty IL-1β biologic therapy disrupt your treatment. We help eligible patients access Ilaris (canakinumab) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Ilaris (canakinumab) is FDA-approved for cryopyrin-associated periodic syndromes (CAPS) including Muckle-Wells syndrome, FCAS, and NOMID; TNF receptor-associated periodic syndrome (TRAPS); hyperimmunoglobulin D syndrome/mevalonate kinase deficiency (HIDS/MKD); familial Mediterranean fever (FMF); active Still's disease (including AOSD and SJIA); and gout flares in adults intolerant to NSAIDs/colchicine. It is an IL-1β monoclonal antibody given as SC injection.
- Without assistance, Ilaris costs commonly run approximately $16,000–$22,000 per dose, with annual costs often $200,000+.
- Through AffordMyPrescriptions, qualifying patients can access Ilaris for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- There is no biosimilar of Ilaris in the U.S. as of 2026. Other IL-1 pathway blockers include anakinra (Kineret, IL-1 receptor antagonist, SC daily, with much lower cost) and rilonacept (Arcalyst, IL-1 trap, SC weekly).
What Is Ilaris Prescription Assistance Program?
The Ilaris Prescription Assistance Program is a manufacturer-sponsored initiative that provides Ilaris at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for autoinflammatory disease and Still’s disease patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, rheumatology coordination, prior-authorization documentation, specialty pharmacy logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and re-certification.
Pharmacy Price Comparison
- Without assistance, Ilaris costs roughly $16,000–$22,000 per dose. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$21,000/dose | Save substantially |
| CVS Pharmacy | ~$22,000/dose | Save substantially |
| Walmart | ~$17,500/dose | Save substantially |
| Costco | ~$17,000/dose | Save substantially |
Specialty Pharmacy | ~$18,500/dose | Save substantially |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Ilaris Prescription Program?
The Patient Assistance Program is free to apply for and provides Ilaris at no medication cost if approved. Our $69.95/month service covers full advocacy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Ilaris:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $16,000–$22,000/dose per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Ilaris assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Ilaris Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Ilaris :
Ilaris (canakinumab) is a fully human monoclonal antibody that specifically binds and neutralizes interleukin-1β (IL-1β) — a key cytokine driving autoinflammation in cryopyrin-associated periodic syndromes, other periodic fever syndromes, Still’s disease, and gout flares.
How Ilaris Works:
The master inflammatory cytokine IL-1β, driven by NLRP3 inflammasome activation, causes chronic systemic inflammation when dysregulated in conditions like CAPS, Still’s disease, and gout flares. Canakinumab is a high-affinity monoclonal antibody that binds directly to IL-1β, preventing it from activating its receptor. Unlike anakinra, which blocks both IL-1α and IL-1β, canakinumab selectively targets only IL-1β. Furthermore, its long half-life allows for convenient dosing every 8 weeks for most indications, providing a major advantage over daily therapies and yielding rapid, dramatic effects in CAPS.
Form and use:
Ilaris is administered via a subcutaneous injection, and it is supplied as either a solution or a reconstituted lyophilized powder depending on the formulation. Dosing frequency and amounts vary heavily by body weight and the specific medical indication being treated. For adults with CAPS weighing 40 kg or more, the standard dose is 150 mg every 8 weeks, whereas TRAPS, HIDS-MKD, FMF, and active Still’s disease require dosing every 4 weeks. Conversely, treating acute gout flares involves just a single 150 mg injection.
Generic availability:
As of 2026, there is no biosimilar version of Ilaris available in the United States. Other existing IL-1 blockers include rilonacept, which is administered weekly, and anakinra, a daily subcutaneous option that is widely used off-label for similar conditions at a substantially lower annual cost. For managing Still’s disease, IL-6 inhibitors like tocilizumab are also commonly utilized. For gout flare management, Ilaris is strictly reserved for refractory cases, while standard options include colchicine, oral or intra-articular steroids, and NSAIDs.
Warnings:
Ilaris carries important warnings regarding serious infections, which includes the potential reactivation of tuberculosis and other latent infections, making pre-treatment screening mandatory. Patients with Still’s disease must be continuously monitored for macrophage activation syndrome (MAS) while receiving therapy. The medication is also associated with warnings for hypersensitivity reactions and specific embryo-fetal considerations. Finally, patients must avoid receiving live vaccines while undergoing treatment with this medication.
FAQ (Frequently Asked Questions)
How Much Does Ilaris Cost Without Insurance?
Ilaris costs approximately $16,000–$22,000 per dose, with annual costs commonly $200,000+ (depending on indication and dosing frequency). Through AffordMyPrescriptions, qualifying patients receive Ilaris at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
How Is Ilaris Different From Anakinra (Kineret)?
Both target the IL-1 pathway. Anakinra (Kineret) is an IL-1 receptor antagonist that blocks both IL-1α and IL-1β — given daily by subcutaneous injection. Canakinumab (Ilaris) is a selective anti-IL-1β monoclonal antibody given every 4–8 weeks depending on indication. Ilaris’s much longer dosing interval is the main practical advantage; anakinra is substantially less expensive but requires daily injections. Both are effective in CAPS and other IL-1-driven conditions.
How Quickly Will Ilaris Work?
For CAPS and other autoinflammatory syndromes, response is typically rapid — within days to weeks of the first dose. For Still’s disease, fever and rash typically resolve within days; joint symptoms may take longer. For gout, fever and pain typically resolve within days of the single dose.
Why Do I Need TB Screening?
IL-1β blockade can reactivate latent tuberculosis. TB screening (PPD or QuantiFERON-Gold) is required before starting. Patients with positive screening typically need TB prophylaxis before or alongside Ilaris.
Can I Get Ilaris Through The PAP If I Have Medicare?
Yes. Medicare Part D beneficiaries can typically qualify, especially if you face specialty-tier copays you cannot afford. The manufacturer’s commercial copay savings program is reserved for commercially insured patients only — but the underlying PAP supports Medicare patients who meet income criteria.
What If My Application Is Denied?
If denied, we explore alternatives — switching to anakinra (Kineret) — substantially lower cost and effective for most IL-1-driven conditions, rilonacept for select indications, Actemra (IL-6) for Still’s disease, the manufacturer’s copay program for commercially insured patients, or independent foundations such as the Autoinflammatory Alliance, Arthritis Foundation, PAN Foundation, or HealthWell Foundation. If we cannot find a path, you won’t be charged our service fee.
Are Live Vaccines Safe On Ilaris?
No. Live vaccines (MMR, varicella, MMRV, yellow fever, oral typhoid) should be avoided while on Ilaris. Inactivated vaccines (flu, pneumococcal, COVID-19, Tdap, HPV) are recommended and safe. Get any needed live vaccines before starting Ilaris.
Take Control of Your Medication Costs
If you are struggling with the high cost of Ilaris, our team may be able to help you access assistance programs designed to make brand specialty IL-1β biologic therapy affordable. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.